Theravance Biopharma (TBPH) Return on Capital Employed (2014 - 2026)
Theravance Biopharma (TBPH) posted quarterly Return on Capital Employed of 0.3% for Q1 2026, up 1611.0% year-over-year from 0.02% in Q1 2025, and up 134.52% quarter-over-quarter from 0.87% in Q4 2025.
Theravance Biopharma (TBPH) Return on Capital Employed (2014 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has reported Return on Capital Employed for 13 consecutive years, with 0.3% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed rose 1611.0% year-over-year to 0.3%; the TTM figure through Mar 2026 stood at 0.3% (up 1611.0% YoY), while the FY2025 annual figure was 0.94%, up 1303.0% from the prior year.
- Return on Capital Employed improved to 0.3% in Q1 2026 per TBPH's latest filing, from 0.87% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 0.3% in Q1 2026 and bottomed at 66.19% in Q1 2022.
- Historically, Return on Capital Employed has averaged 18.44% across 5 years, with a median of 14.33% in 2023.
- Annual changes were most pronounced in 2022 — Return on Capital Employed soared 6403 bps — and 2025, when it tumbled 389 bps.
- Theravance Biopharma's Return on Capital Employed stood at 14.0% in 2022, then retreated by 7 bps to 15.02% in 2023, then rose by 3 bps to 14.53% in 2024, then soared by 94 bps to 0.87% in 2025, then surged by 135 bps to 0.3% in 2026.
- Business Quant data shows TBPH's Return on Capital Employed at 0.3% in Q1 2026, 0.87% in Q4 2025, and 8.56% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Theravance Biopharma | 880.59 Mn | 492.93 Mn | - | -0.95% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.95% |
| Mar 31, 2026 | 0.30% |
| Dec 31, 2025 | -0.87% |
| Sep 30, 2025 | -8.56% |
| Jun 30, 2025 | -11.27% |
| Mar 31, 2025 | -15.81% |
| Dec 31, 2024 | -14.53% |
| Sep 30, 2024 | -13.11% |
| Jun 30, 2024 | -12.19% |
| Mar 31, 2024 | -11.92% |
| Dec 31, 2023 | -15.02% |
| Sep 30, 2023 | -16.61% |
| Jun 30, 2023 | -14.45% |
| Mar 31, 2023 | -14.33% |
| Dec 31, 2022 | -14.00% |
| Sep 30, 2022 | -31.12% |
| Jun 30, 2022 | -53.82% |
| Mar 31, 2022 | -66.19% |
| Dec 31, 2021 | -78.03% |
| Sep 30, 2021 | -79.44% |